A Phase 2 Open-Label, Randomized Controlled Trial to Evaluate the Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec in Participants With Moderate COVID-19 Disease
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Telacebec (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Qurient Co
- 12 Feb 2022 Status changed from recruiting to discontinued.
- 29 Jul 2021 Status changed from not yet recruiting to recruiting.
- 14 Apr 2021 Status changed from planning to not yet recruiting.